Huma Multiple Myeloma Cell line, AMO1, treated with NCP26, LC-MSMS analysis

ABSTRACT: The human multiple myeloma cell line, AMO1, was treated with NCP26, an ATP-competitive EPRS inhibitor, and a total proteome-wide analysis was performed to determine the effect of NCP26 treatment on protein dynamics.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Plasma Cell, Multiple Myeloma Cell Line

DISEASE(S): Multiple Myeloma

SUBMITTER: Keiji Kurata  

LAB HEAD: Kenneth Carl Anderson

PROVIDER: PXD029453 | Pride | 2023-03-11

REPOSITORIES: Pride